



Nuplazid[®] (pimavanserin) – New formulation

- On June 29, 2018, [Acadia Pharmaceuticals announced](#) the FDA approval of [Nuplazid \(pimavanserin\)](#) 34 mg capsules for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.
 - Previously, Nuplazid was available as a 17 mg tablet.
- Administration of one 34 mg capsule once daily results in plasma Nuplazid concentrations that are similar to exposure with two 17 mg tablets once daily.
- In addition, a new 10 mg strength tablet will be available to support patients who are concomitantly receiving strong cytochrome 3A4 inhibitors, which can inhibit the metabolism of Nuplazid.
- Nuplazid carries a boxed warning regarding increased mortality in elderly patients with dementia-related psychosis.
- Other warnings and precautions of Nuplazid include QT interval prolongation.
- The most common adverse reactions ($\geq 5\%$ and twice the rate of placebo) with Nuplazid use were peripheral edema and confusional state.
- The recommended dose of Nuplazid is 34 mg orally once daily, without titration.
 - The recommended dose for patients who are concomitantly receiving strong CYP3A4 inhibitors is 10 mg orally once daily.
 - Patients who are concomitantly receiving strong CYP3A4 inducers should be monitored for reduced efficacy of Nuplazid. An increase in Nuplazid dosage may be needed in these patients.
- Acadia plans to launch Nuplazid 34 mg capsules and 10 mg tablets by mid-August 2018. The 34 mg capsules will replace the currently available 17 mg tablets.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at optum.com.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.